Long-term use of low-dose spironolactone in spontaneously hypertensive rats: Effects on left ventricular hypertrophy and stiffness

Avanza, 2000, Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan, Arq Bras Cardiol, 74, 111, 10.1590/S0066-782X2000000200001 Baldo, 2011, Effect of spironolactone in adult spontaneously hypertensive rats submitted to high salt intake, Clinics, 66, 477, 10.1590/S1807-59322011000300020 Baumann, 2007, Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage, J Hypertens, 25, 2504, 10.1097/HJH.0b013e3282ef84f8 Bos, 2005, Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist, J Cardiovasc Pharmacol, 45, 8, 10.1097/00005344-200501000-00003 Brilla, 1992, Reactive and reparative myocar-dial fibrosis in arterial hypertension in the rat, Cardiovasc Res, 26, 671, 10.1093/cvr/26.7.671 Cabassi, 2007, Characterization of myocardial hypertrophy in prehypertensive spontaneously hypertensive rats: interaction between adrenergic and nitrosative pathways, J Hypertens, 25, 1719, 10.1097/HJH.0b013e3281de72f0 Cabassi, 1998, Regional sympathetic activity in prehypertensive phase of spontaneously hypertensive rats, Life Sci, 62, 1111, 10.1016/S0024-3205(98)00034-4 Calhoun, 2007, Low-dose aldosterone blockade as a new treatment paradigm for controlling resistance hypertension, J Clin Hypertens, 9, 19, 10.1111/j.1524-6175.2007.06334.x Gaddam, 2010, Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism. A prospective clinical study, Hypertension, 55, 1137, 10.1161/HYPERTENSIONAHA.109.141531 Izawa, 2005, Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dys-function and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study, Circulation, 112, 2940, 10.1161/CIRCULATIONAHA.105.571653 Kambara, 2003, Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure, J Cardiovasc Pharmacol, 41, 830, 10.1097/00005344-200306000-00002 Konishi, 2003, The possible roles of mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hyper-tensive rat, J Ster Biochem Mol Biol, 85, 439, 10.1016/S0960-0760(03)00198-5 Kuster, 2005, Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload, Circulation, 111, 420, 10.1161/01.CIR.0000153800.09920.40 Maron, 2010, Aldosterone receptor antagonists. Effective but often forgotten, Circulation, 121, 934, 10.1161/CIRCULATIONAHA.109.895235 Mill, 2003, Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats, Clin Exp Pharmacol Physiol, 30, 739, 10.1046/j.1440-1681.2003.03906.x Ohtani, 2007, Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker, Am J Physiol Heart Circ Physiol, 292, 946 Okoshi, 2004, Aldosterone directly stimulates cardiac myocyte hypertrophy, J Card Fail, 10, 511, 10.1016/j.cardfail.2004.03.002 Otsuka, 1998, Interaction of mRNAs for angiotension II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats, Hypertension, 32, 467, 10.1161/01.HYP.32.3.467 Pitt, 2003, Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-left ventricular hypertrophy study, Circulation, 108, 1831, 10.1161/01.CIR.0000091405.00772.6E Pitt, 1999, The effect of spironolac-tone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Resende, 2006, Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats, Life Sci, 78, 3066, 10.1016/j.lfs.2005.12.011 Rocha, 2010, Kinetics of cardiac and vascular remodeling by spontaneously hypertensive rats after discontinuation of long-term captopril treatment, Braz J Med Biol Res, 43, 390, 10.1590/S0100-879X2010007500023 Susic, 2007, Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR, Am J Physiol Heart Circ Physiol, 292, 175, 10.1152/ajpheart.00660.2006 Susic, 2005, Beneficial cardiovascular actions of eplerenone in the spontaneously hypertensive rat, J Cardiovasc Pharmacol Ther, 10, 197, 10.1177/107424840501000308 Swedberg, 1990, Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality, Circulation, 82, 1730, 10.1161/01.CIR.82.5.1730 Swynghedauw, 1999, Molecular mechanisms of myocardial remodeling, Physiol Rev, 79, 215, 10.1152/physrev.1999.79.1.215 Takeda, 2000, Cardiac aldosterone production in genetically hyper-tensive rats, Hypertension, 36, 495, 10.1161/01.HYP.36.4.495 Varagic, 2002, Local cardiac renin-angiotensin system: hypertension and cardiac failure, J Mol Cell Cardiol, 34, 1435, 10.1006/jmcc.2002.2075 Veliotes, 2005, Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by β-adrenoreceptor activation, Hypertension, 45, 914, 10.1161/01.HYP.0000164567.62172.c5 Wright, 2008, Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies, Heart Fail Rev, 13, 367, 10.1007/s10741-007-9060-z